The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
CCL2 as an Important Mediator of Prostate Cancer Growth In Vivo through the Regulation of Macrophage Infiltration
Open accessAbstract
The ability of CCL2 to influence prostate cancer tumorigenesis and metastasis may occur through two distinct mechanisms: 1) a direct effect on tumor cell growth and function, and 2) an indirect effect on the tumor microenvironment by the regulation of macrophage mobilization and infiltration into the tumor bed. We have previously demonstrated that CCL2 exerts a direct effect on prostate cancer epithelial cells by the regulation of their growth, invasion, and migration, resulting in enhanced tumorigenesis and metastasis. Here we describe an indirect effect of CCL2 on prostate cancer growth and metastasis by regulating monocyte/macrophage infiltration into the tumor microenvironment and by stimulating a phenotypic change within these immune cells to promote tumor growth (tumor-associated macrophages). VCaP prostate cancer cells were subcutaneously injected in male SCID mice and monitored for tumor volume, CD68(+) macrophage infiltration, and microvascular density. Systemic administration of anti-CCL2 neutralizing antibodies (CNTO888 and C1142) significantly retarded tumor growth and attenuated CD68(+) macrophage infiltration, which was accompanied by a significant decrease in microvascular density. These data suggest that CCL2 contributes to prostate cancer growth through the regulation of macrophage infiltration and enhanced angiogenesis within the tumor.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Coussens, L. M., & Werb, Z. (2002) · Nature · doi:10.1038/nature01322 · Cited by 15,111
Research works printed but not linked: 14
- Taichman, 2002, Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone, Cancer Res, 62, 1832
- Vanderkerken, 2002, Monocyte chemoattractant protein1 (MCP-1), secreted by bone marrow endothelial cells, induces chemoattraction of 5T multiple myeloma cells, Clin Exp Metastasis, 19, 87, 10.1023/A:1013891205989 · doi:10.1023/a:1013891205989
- Ohta, 2002, Monocyte chemoattractant protein-1 expression correlates with macrophage infiltration and tumor vascularity in human esophageal squamous cell carcinomas, Int J Cancer, 102, 220, 10.1002/ijc.10705 · DOI
- Valkovic, 1998, Expression of monocyte chemotactic protein-1 in human invasive ductal breast cancer, Pathol Res Pract, 194, 335, 10.1016/S0344-0338(98)80057-5 · DOI
- Lebrecht, 2004, Monocyte chemoattractant protein-1 serum levels in patients with breast cancer, Tumour Biol, 25, 14, 10.1159/000077718 · DOI
- Loberg, 2006, CCL2 is a potent regulator of prostate cancer cell migration and proliferation, Neoplasia, 8, 578, 10.1593/neo.06280 · DOI · Paper page
- Lu Y Cal, 2006, Monocyte chemotactic protein-1 (MCP-1) acts as a paracrine and autocrine factor for prostate cancer growth and invasion, Prostate, 66, 1311, 10.1002/pros.20464 · DOI · Paper page
- Korenchuk, 2001, VCaP, a cell-based model system of human prostate cancer, In Vivo, 15, 163
- Loberg, 2006, Development of the VCaP androgen-independent model of prostate cancer, Urol Oncol, 24, 161, 10.1016/j.urolonc.2005.11.005 · DOI
- Zhou, 2004, Progression to androgen-independent LNCaP human prostate tumors: cellular and molecular alterations, Int J Cancer, 110, 800, 10.1002/ijc.20206 · DOI
- Lu Y Cai, 2007, Monocyte chemotactic protein-1 mediates prostate cancer-induced bone resorption, Cancer Res, 67, 3646, 10.1158/0008-5472.CAN-06-1210 · DOI · Paper page
- Balkwill, 2001, Inflammation and cancer: back to Virchow?, Lancet, 357, 539, 10.1016/S0140-6736(00)04046-0 · DOI · Paper page
- Lu, 2006, Inflammation, a key event in cancer development, Mol Cancer Res, 4, 221, 10.1158/1541-7786.MCR-05-0261 · DOI · Paper page
- Loberg RD, Bradley DA, Pienta KJ (in press). The lethal phenotype of cancer: the molecular basis of death due to malignancy. Cancer. · DOI · Paper page
Cited by
The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment
Kumar, V., Patel, S., Tcyganov, E., & Gabrilovich, D. I. (2016) · Trends in Immunology · doi:10.1016/j.it.2016.01.004 · Cited by 2,008
Targeting macrophages: therapeutic approaches in cancer
Cassetta, L., & Pollard, J. W. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.169 · Cited by 2,048
Therapeutic Targeting of the Tumor Microenvironment
Bejarano, L., Jordāo, M. J. C., & Joyce, J. A. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1808 · Cited by 1,653
The role of myeloid cells in the promotion of tumour angiogenesis
Murdoch, C., Muthana, M., Coffelt, S. B., & Lewis, C. E. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2444 · Cited by 1,642
MCP-1: Function, regulation, and involvement in disease
Singh, S., Anshita, D., & Ravichandiran, V. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.107598 · Cited by 883
Inflammation: Gearing the journey to cancer
KUNDU, J., & SURH, Y. (2008) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2008.03.002 · Cited by 803
Key chemokines direct migration of immune cells in solid tumors
Kohli, K., Pillarisetty, V. G., & Kim, T. S. (2022) · Cancer Gene Therapy · doi:10.1038/s41417-021-00303-x · Cited by 583
Targeting the CCL2-CCR2 signaling axis in cancer metastasis
Lim, S. Y., Yuzhalin, A. E., Gordon-Weeks, A. N., & Muschel, R. J. (2016) · Oncotarget · doi:10.18632/oncotarget.7376 · Cited by 501
Pienta, K. J., Machiels, J.-P., Schrijvers, D., Alekseev, B., Shkolnik, M., Crabb, S. J., Li, S., Seetharam, S., Puchalski, T. A., Takimoto, C., et al. (2013) · Investigational New Drugs · doi:10.1007/s10637-012-9869-8 · Cited by 412
Self-citationRole of the CCL2‐CCR2 signalling axis in cancer: Mechanisms and therapeutic targeting
Xu, M., Wang, Y., Xia, R., Wei, Y., & Wei, X. (2021) · Cell Proliferation · doi:10.1111/cpr.13115 · Cited by 382
The chemokine system in cancer biology and therapy
Mantovani, A., Savino, B., Locati, M., Zammataro, L., Allavena, P., & Bonecchi, R. (2010) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2009.11.007 · Cited by 393
Tissue macrophages: origin, heterogenity, biological functions, diseases and therapeutic targets
Guan, F., Wang, R., Yi, Z., Luo, P., Liu, W., Xie, Y., Liu, Z., Xia, Z., Zhang, H., & Cheng, Q. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02124-y · Cited by 371
Molecular networks that regulate cancer metastasis
Spano, D., Heck, C., De Antonellis, P., Christofori, G., & Zollo, M. (2012) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2012.03.006 · Cited by 357
Sandhu, S. K., Papadopoulos, K., Fong, P. C., Patnaik, A., Messiou, C., Olmos, D., Wang, G., Tromp, B. J., Puchalski, T. A., Balkwill, F., et al. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-013-2099-8 · Cited by 272
The CCL20-CCR6 Axis in Cancer Progression
Kadomoto, S., Izumi, K., & Mizokami, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21155186 · Cited by 267
CC chemokine ligand 2 (CCL2) promotes prostate cancer tumorigenesis and metastasis
Zhang, J., Patel, L., & Pienta, K. J. (2010) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2009.11.009 · Cited by 261
Self-citationMesenchymal stem cell secretome and regenerative therapy after cancer
Zimmerlin, L., Park, T. S., Zambidis, E. T., Donnenberg, V. S., & Donnenberg, A. D. (2013) · Biochimie · doi:10.1016/j.biochi.2013.05.010 · Cited by 168
“The immunosuppressive activity of MCP1 has been implicated in the progression and metastasis of cancer in animal models of skin papilloma [133], colon carcinoma [134], prostate cancer [135], breast cancer [136, 137] and lung cancer [138].”
BackgroundOpportunities and challenges in combination gene cancer therapy
Nastiuk, K. L., & Krolewski, J. J. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.12.005 · Cited by 85
Lee, S. W. L., Seager, R. J., Litvak, F., Spill, F., Sieow, J. L., Leong, P. H., Kumar, D., Tan, A. S. M., Wong, S. C., Adriani, G., et al. (2020) · Integrative Biology · doi:10.1093/intbio/zyaa007 · Cited by 60
Metadata
- Authors
- Loberg, R. D., Ying, C., Craig, M., Yan, L., Snyder, L. A., & Pienta, K. J.
- Venue
- Neoplasia
- Publisher
- Elsevier BV
- Published
- 2007-07
- Volume
- 9
- Issue
- 7
- Pages
- 556-562
- ISSN
- 1476-5586 (ISSN-L)
- OpenAlex
- W2090754742
- Cited by
- 242
- References
- 1
- FWCI
- 4.83
- Type
- journal article
- Language
- en
- Open access
- gold
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by-nc-nd/3.0/ (vor, 2500 d)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.